PHCentral RSS - rss FIRE feed Fri, 21 Nov 2014 11:11:19 GMT New Stem Cell Treatment for IPF November 21, 2014 ...a team of researchers, Amiq Gazdhar and colleagues, sought to evaluate the potential of induced pluripotent stem cells (iPSC) conditioned media (iPSC-cm) to regenerate and repair the alveolar epithelium in vitro and improve bleomycin induced lung injury in vivo....
The most common cause of death related to IPF is respiratory failure. Other causes of death include pulmonary hypertension, heart failure, pulmonary embolism, pneumonia, and lung cancer....recently, cell based approaches have been proposed as new possibilities to regenerate various organs, including the fibrotic lung.

The generation of human induced pluripotent stem cells (iPSC) has opened up a new avenue for patient-specific cell based therapies.
In this study, researchers showed that conditioned media obtained from iPSC improved alveolar epithelial repair in vitro and attenuated bleomycin induced lung injury and fibrosis in vivo]]>
Pulmonary Arterial Hypertension: A Better Understanding of the Three New Drug Therapies November 21, 2014
Medscape: I understand that three new drugs to treat PAH have been approved in the past year or two.
Dr Nathan: Yes, indeed. The three drugs are riociguat (Adempas®), which acts on the nitric oxide pathway and further downstream as a direct guanylate cyclase stimulator, as well as sensitizing the receptor to endogenous nitric oxide. The second is an endothelin receptor antagonist (ERA) called macitentan (Opsumit®). The third is oral treprostinil, marketed as Orenitram™, which is the same compound as the treprostinil that is now used for intravenous, subcutaneous, or inhaled administration.....
Medscape: Where do you think the menu of treatments for PAH is going?
Dr Nathan: Thankfully, despite the availability of many treatment options, there's growing interest in developing new drugs. There are a number of agents in development beyond the currently available drugs, which mainly address the balance between vasodilation and vasoconstriction. These investigational therapies include antiproliferative agents, aimed at the root cause of PAH, with the potential of being more potent disease modifiers.]]>
AHA’s Scholarly Journal Plans New Thematic Series Covering Advances in PH November 20, 2014 PH Therapy Riociguat To Be Tested as Diffuse Cutaneous Systemic Sclerosis Drug November 19, 2014 PH Patients Meet with Congress November 19, 2014 Screening for Connective Tissue Disease in Pulmonary Arterial Hypertension November 18, 2014 Delhi doctors cure Zimbabwean woman of rare artery disorder November 17, 2014
Doctors in Zimbabwe began medication and expected a speedy recovery. However, despite going through extensive treatment, she had no relief...That’s when the doctors decided to start from scratch. They found out that Margaret's pulmonary artery pressure was 120 mmHG, when it should have been between 18 and 30 mmHG.

Medical tests later confirmed that she was actually suffering from a rare condition called isolated pulmonary artery stenosis.

“We carried out a CT scan of the lungs and angiography of the right side of her heart. We found out that branches of arteries going to the lungs were completely blocked. This blockage was not detectable in a cardiac echo,” said Dr Naveen Bhamri, associate director in cardiology department at Max Hospital, Shalimar Bagh.
Two days after the surgery, Margaret was discharged. The overall treatment cost her about Rs 1.5 lakh.

“Now, I am even fit to participate in a marathon. After being bothered by this disorder for 20 years, it is hard to believe that I have been relieved from the ailment,” a cheerful Margaret said]]>
Newly Identified Blood Signatures Help Map Successful PAH Treatments November 16, 2014 New Insights For Cardiac Assessment Before Administering Stem Cell Therapy in Scleroderma November 16, 2014 The Journal of the American Medical Association, entitled “Cardiac Assessment Before Stem Cell Transplantation for Systemic Sclerosis,” Dr. Burt at the Division of Immunotherapy, Northwestern University and colleagues highlight the importance of performing extensive cardiopulmonary screening in patients with severe forms of systemic sclerosis before administrating HSCT.]]> Combination Therapy for PAH: AMBITION Study Yields Impressive Results November 15, 2014 Riociguat benefits subgroup of pulmonary hypertension patients November 15, 2014 HMG-COA reductase inhibitors: An opportunity for the improvement of imatinib safety. An experimental study in rat pulmonary hypertension November 14, 2014 American Heart Association Publishes Major Update on Pulmonary Hypertension Advances November 13, 2014 The dangers from dust November 13, 2014 Indian scientists find cure for pulmonary blood pressure November 13, 2014 ]]> Australia leads in pulmonary hypertension survival November 13, 2014 Scientists Identify a Role for Carbon Monoxide in Battling Bacterial Infections November 12, 2014 Now, a research team led by investigators at Beth Israel Deaconess Medical Center (BIDMC) finds that naturally occurring carbon monoxide (CO) is essential for the macrophages’ carefully crafted surveillance plan and subsequent attack...]]> Safety Concerns Disqualify Scleroderma/PH Patients for Stem Cell Trial November 12, 2014 Clinical Diagnosis of Pulmonary Hypertension November 11, 2014 Detailed fulltext article
Pulmonary Hypertension Diagnosis Aided By HD Medical's New Visual Murmur Stethoscope November 10, 2014 Heart murmurs are characteristic signs of turbulent blood flow in cardiovascular structures. They can alert a physician to a stenosed artery, malfunctioning valve, and blood back flow, such as in PH, where the right side of the heart becomes congested because blood cannot adequately enter the lung vasculature.]]> Magnetic resonance imaging may accurately measure pulmonary hypertension November 10, 2014 Novel miRNAs and Molecule Inhibitors to Treat PAH November 9, 2014 Patient Inspires Kids With Rare Lung Disease November 9, 2014 Unlocking the secrets of pulmonary hypertension November 8, 2014 Lung Donation After Cardiac Death Shows Promise November 8, 2014 Researchers Discover What Leads To Metabolic Remodeling of PAH Patients’ Pulmonary Arteries, Extra Pulmonary Tissues November 7, 2014 Physical Exam Unreliable in Predicting Pulmonary Hypertension November 7, 2014 Pulmonary Arterial Hypertension Reveals Characteristics Similar To Diabetes, Cancer November 6, 2014 Researchers Show How Microvasculature is Involved in CTEPH Pathogenesis November 6, 2014 Pulmonary Hypertension Treatment Guidelines Updated At Recent ACCP Meeting November 6, 2014 Males With Scleroderma Found To Be More Affected By Pulmonary Hypertension November 5, 2014 Better Quality of Life May Improve Pulmonary Hypertension Survival November 4, 2014 £7.5 million boost for world-leading lung imaging research November 3, 2014 Utility of the Physical Examination in Detecting Pulmonary Hypertension. A Mixed Methods Study November 2, 2014 Erectile-Dysfunction Drugs Also Give the Heart a Boost November 2, 2014 Keeping Pace With Evidence-Based Medicine: Pulmonary Hypertension Guideline Updates and Beyond November 1, 2014 ProMetic Submits Idiopathic Pulmonary Fibrosis Therapy PBI-4050 For Orphan Drug Status November 1, 2014 Implant Eliminates External Pump in Pulmonary Hypertension October 31, 2014 Researchers find novel way to treat pulmonary arterial disease October 31, 2014 Liver Disease Can Cause Pulmonary Hypertension October 31, 2014 New Overview Underscores Recent Progress in PAH Treatments October 30, 2014 Scleroderma-Related PAH October 30, 2014 Lack of transcription factor FoxO1 triggers pulmonary hypertension October 29, 2014 ‘Dead heart’ transplant breakthrough at St Vincent’s Hospital October 29, 2014 New Pulmonary Arterial Hypertenion Research Highlights PAH-Related Myopathy, Importance of Exercise October 29, 2014 ...
Skeletal muscles of PAH patients show a wide spectrum of cellular abnormalities that finally culminate in muscle atrophy and reduced contractility. Exercise training improves muscle function and bears a positive impact on clinical outcomes of PAH patients.]]>
Sildenafil-Treated PAH, Scleroderma Patient Shows Remarkable Improvements October 28, 2014 ...
This case study adds to a previous report of a patient with small vessel vasculitis and Takayasu arteritis. In both studies, sildenafil was credited with enhancing vasodilation and inhibiting over proliferation of cells that can thicken vessel walls. These two successes led the authors to conclude that sildenafil ought to be further exploited for the treatment of patients with pulmonary arterial hypertension associated with scleroderma.]]>
Caution Around Potting Mix October 27, 2014 Rho-kinase inhibitor decreased pulmonary vascular resistance and pressure, right ventricular hypertrophy and systolic dysfunction October 27, 2014 ..
The inhaled Rho-kinase inhibitor normalized pulmonary vascular resistance and rescued right ventricular hypertrophy and pulmonary arterial wall remodeling.

HRQoL goals may improve outcome in PAH October 26, 2014 How 'vampire op' sucked all the blood from me to help me breathe again October 26, 2014
Yet surgeons were saving her life. Annette was undergoing a pulmonary endarterectomy, a pioneering operation which put her into a corpse-like state as a heart-lung machine took over the work of these vital organs and her blood was removed.]]>
Echocardiographic Prediction of Pre- versus Postcapillary Pulmonary Hypertension October 25, 2014 An Update on Scleroderma-Related PAH October 25, 2014 Current Opinion in Rheumatology by Dr. Kristin Highland at the Respiratory Institute in the Cleveland Clinic Foundation, concisely reviewed the wealth of knowledge gained over the years relating to scleroderma and pulmonary hypertension.]]> Vascular receptor autoantibodies implicated in SSc-PAH October 25, 2014 ‘Dead heart’ transplant breakthrough at St Vincent’s Hospital October 24, 2014 New PAH Research Highlights Effect of Disease on Muscles, Importance of Exercise October 24, 2014 Plant grown treatment for pulmonary hypertension October 24, 2014
In studies, Pharmaceutical International reports, the drug has been administered to rats. These studies found that the pulmonary hypertension levels in the rats dropped by around 20 percent. After two weeks of administration, the pressure levels inside the rats decreased by a further 12 percent. The rat based-trials not only produced pulmonary hypertension pressure drops of more than 30 percent, the drug further helped to improve heart function. The studies were conducted by the American Heart Association and the National Heart, Lung and Blood Institute.]]>
Actelion intends to file for selexipag's approval for PAH in the U.S. and the EU soon October 23, 2014 According to Actelion's 3Q Earnings-Report..]]>